Dose-response Relationship of Botullinum Toxin (DWP 450) for Finger Flexor Spasticity
Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Study Design: Randomized Single Blind Study Objective: To determine the dose relationship of
DWP 450 for finger flexor spasticity Subjects: 78 patients with upper extremity spasticity
after CVA Inclusion criteria: Patient who have spasticity (MAS greater than 2 in finger
flexors) Methods: Patients will be randomly assigned to one of 5 groups. Gp 1: placebo, Gp 2:
15U, Gp 3: 30 U, Gp 4: 50 U, Gp 5: 75 U
Phase:
Phase 4
Details
Lead Sponsor:
Seoul National University Hospital
Collaborator:
Daewoong Pharmaceutical Co. LTD.
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A onabotulinumtoxinA